Germany

Germany operates within the European Union regulatory framework, meaning health product approvals are governed by a combination of EU-level legislation and national implementation. The primary national authorities are the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM), which oversees pharmaceuticals, medical devices, diagnostics, and digital health applications, and the Paul-Ehrlich-Institut (PEI), which holds responsibility for biologicals, vaccines, and blood products. Pharmaceutical approvals may follow the centralized procedure via the European Medicines Agency (EMA), the mutual recognition procedure (MRP), the decentralized procedure (DCP), or the national procedure for products marketed solely in Germany. Medical devices are regulated under EU MDR 2017/745 and EU IVDR 2017/746, requiring CE marking through accredited Notified Bodies rather than a direct governmental approval process. Digital health applications (Digitale Gesundheitsanwendungen, DiGA) follow a unique fast-track pathway administered by BfArM under the Digital Healthcare Act (DVG), with a provisional approval possible within three months.

Submission dossiers for pharmaceuticals must conform to the Common Technical Document (CTD) format, consistent with ICH guidelines and EU requirements, with electronic submissions (eCTD) now standard for centralized and most national procedures. A local EU-based Marketing Authorization Holder (MAH) or representative is mandatory for all pharmaceutical submissions, and a local Qualified Person (QP) must be designated for batch release within the EU. For medical devices, technical documentation must meet the requirements of EU MDR/IVDR annexes, including clinical evaluation reports, post-market surveillance plans, and, for higher-risk devices, involvement of a Notified Body. Recent reforms of note include the phased enforcement of EU MDR and IVDR transition timelines, the ongoing expansion of the DiGA pathway to include digital medical devices (DiPA) for care settings, and increasing regulatory attention to AI-enabled medical devices under evolving EU guidance. Germany has also been active in shaping the proposed EU Health Technology Assessment (HTA) Regulation (EU 2021/2282), which became applicable in January 2025 and introduces joint clinical assessments for new medicines and certain medical devices at the EU level.

Germany has a highly decentralized procurement structure reflecting its federal system, in which health policy responsibilities are shared between the federal government and the 16 federal states (Laender). The statutory health insurance (Gesetzliche Krankenversicherung, GKV) system covers approximately 90 percent of the population and is administered through more than 90 competing non-profit sickness funds (Krankenkassen), coordinated nationally by the GKV-Spitzenverband (GKV-SV). Pharmaceutical reimbursement and pricing are governed by the Act on the Reform of the Market for Medicinal Products (AMNOG, 2011), under which newly launched pharmaceuticals with claimed additional benefit undergo a mandatory early benefit assessment (Nutzenbewertung) by the Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA), followed by price negotiations between manufacturers and GKV-SV. For medical devices, hospitals and ambulatory care providers procure independently or through group purchasing organizations (GPOs), with procurement for hospital-based devices subject to public tendering rules under EU Directive 2014/24/EU as transposed into German law (GWB, VgV). Diagnostics and digital health solutions are increasingly subject to structured assessment pathways, with DiGA reimbursement negotiated directly between manufacturers and GKV-SV following BfArM listing.

Germany does not rely on donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, as it is a high-income country and a significant contributor to these mechanisms rather than a recipient. The private health insurance (Private Krankenversicherung, PKV) sector covers approximately 10 percent of the population and procures health products through contractual arrangements with providers, generally offering broader formulary access and higher reimbursement rates than GKV. Germany does not enforce explicit local manufacturing preference policies in health procurement; however, the COVID-19 pandemic has prompted EU-level and national strategic interest in securing domestic and European manufacturing capacity for critical health products, including active pharmaceutical ingredients (APIs), vaccines, and diagnostics, reflected in initiatives such as the European Health Emergency Preparedness and Response Authority (HERA) and national pandemic preparedness planning. Tenders for hospital supplies and diagnostics at the Laender level may incorporate quality, supply security, and sustainability criteria that indirectly favor established European suppliers.